Q4 2024 Earnings Call Transcript February 13, 2025 DexCom, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.4792. Operator: Thank you for standing by. My name is ...

At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines have been placed on mute to prevent any background noise. After the ...

We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...

Android 16 will feature Fitbit integration for seamless access to medical records, enhancing health-tracking capabilities for ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...

Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings tomorrow after the bell. Here’s what investors should know. DexCom met analysts’ revenue expectations last quarter ...

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue ...

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million. DexCom reported mixed earnings, with revenue surpassing estimates but earnings per share falling short. DexCom ...

The California-based device maker is pinning its hopes on Stelo, its recently launched device for adults aged 18 and older who do not use insulin, making it the first CGM available for over-the ...

Stifel Nicolaus analyst Mathew Blackman reiterated a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The company’s shares closed yesterday at $84.09.